We are transforming the treatment of diabetic foot disease by curing from within.
Triovance was founded to develop innovative treatments for diabetes, inspired by the founders' personal loss of their fathers to the disease. The company began in Mexico, focusing on gene and cell therapies, and in 2019 secured funding from Jaime Cervantes, president of the Vitalmex Group, to tackle diabetic foot ulcers. After five years of research, Triovance developed a breakthrough skin substitute designed to be safe, affordable, and accessible for low-income patients.
In 2023, Triovance received FDA feedback during its first pre-IND meeting, leading to the formation of Triovance Holding LLC in San Diego, CA.
With an experienced manufacturing team and support from Azzur Cleanrooms on Demand, the company scaled production under Good Manufacturing Practices (GMP). Triovance is driven by an experienced team, expert advisors and key partners, who are all committed to expanding operations and delivering life-changing solutions for patients in need.
Our mission is to improve the quality of life of patients with chronic-degenerative diseases such as diabetes with innovative products based on tissue engineering, gene therapy and cell therapy.
Meet the team behind Triovance
Executive Team
Our mission is to improve the quality of life of patients with chronic-degenerative diseases such as diabetes with products based ontissue engineering, gene therapy, and cell therapy.
Blanca Segura, PhD
Blanca is a 20+ year cell and gene therapy expert and seasoned inventor of innovative research methods and medical devices, including co-development of an epigenetic drug and co-invention of two medical devices for diabetes. As founder and CEO of Triovance, she leads the company in advancing a portfolio of products that address type 2 diabetes and its complications. Previously, she served as CSO at Global BioTherapeutics and PI and researcher at the National Cancer Institute, Mexico.
Jaime Cervantes
Jaime is a visionary entrepreneur and leadership expert with over 30 years of experience in healthcare innovation and business management. He founded Triovance in 2023. He has played a pivotal role in advancing healthcare systems in Latin America through collaboration between public and private sectors. He is the co-inventor of a ventricular assist device developed by Vitalmex, where he previously served as CEO. He also owns Gimmi Gmbh in Germany.
Ian Wisenberg
Ian is an international business expert with over 35 years of experience, specializing in corporate development, finance and strategic partnerships. He has played a key role in helping companies access global markets across the U.S., Europe, and Asia. Currently, Ian serves as Executive Director of Triovance, Managing Director of BioGlobal Consulting Group and Director of LBT Innovations. Previously, Ian served as CEO, Co-founder and Executive Chairman of BioCina, and CFO of BioDuro.
Clinical & Scientific Advisors
Head of Angiology, Vascular and Endovascular Surgery at C.M.N.20 Nov. ISSSTE. Mexico. Master's degree in Advanced Wound in Germany. Research Fellow at the Arizona Heart Institute. Fellow in Surgical Research at the Borgess Medical Center Surgical Research Institute
UT Southwestern Medical Center. Dallas, Texas. Nationally renowned foot and ankle clinician and researcher, who is recognized internationally for his work in limb salvage, management of diabetes-related complications, and education.
30+ years commercial experience in life sciences, focusing on cell & gene therapy. Co-founder of numerous companies, Senior VP of R&D at New York Stem Cell Fdn, Co-author of 30+ published papers, inventor on 50+ patents worldwide, and has filed over 15 INDs at the FDA.
Scientific leader with extensive experience in small/emerging biotech companies and biopharmaceutical organizations. Expertise in oncology, gene therapy, drug delivery, and pharmacokinetics with contributions to all stages of drug development from IND (e.g., Herceptin®, Adstiladrin® gene therapy) through BLA and US/EU approval (e.g., HYQVIA™, HYLECTA™)
